Beta-blocker benefit according to severity of heart failure

European Journal of Heart Failure

Volumn 5, Issue 3, 2003, Pages 281-289

  Bouzamondo, Anissa ^a   Hulot, Jean Sébastien ^a   Sanchez, Paola ^a   Lechat, Philippe ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Beta blockers; Heart failure; Meta analysis; Mortality; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; BISOPROLOL; CARBAZOLES; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; METOPROLOL; PROPANOLAMINES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041940249     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(03)00042-4     Document Type: Article

References (37)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9-13.
2. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7.
3. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8.
4. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
5. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5.
6. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
7. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
8. Avezum A, Tsuyuki RT, Pogue J, Yusuf S. Beta-blocker therapy for congestive heart failure: a systemic overview and critical appraisal of the published trials. Can J Cardiol 1998;14:1045-53.
9. Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000;160:621-7.
10. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-73.
11. Lechat P. Design of the cardiac insufficiency bisoprolol study II (CIBIS II). The CIBIS II Scientific Committee. Fundam Clinical Pharmacol 1997;11:138-42.
12. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
13. Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990;82:473-83.
14. Eichhorn EJ, McGhie AL, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73.
15. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
16. Leff AR, Garrity ER, Munoz NM, et al. Selectivity of the intrinsic sympathomimetic activity of the beta-adrenergic blocking drug bucindolol. J Cardiovasc Pharmacol 1984;6:859-66.
17. Stanton HC, Dungan KW. In vitro effects of beta adrenoceptor agonists and antagonists on the rat ovarian suspensory ligament. J Pharmacol Exp Ther 1986;239:591-6.
18. Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, Bohm M. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000;130:1131-9.
19. Bundkirchen A, Brixius K, Bolck B, Schwinger RH. Bucindolol exerts agonistic activity on the propranolol-insensitive state of beta1-adrenoceptors in human myocardium. J Pharmacol Exp Ther 2002;300:794-801.
20. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105:2429-34.
21. Bristow MB, Abraham WT. Sympatholytic effect of bucindolol adversely affected survival, and was disproportionately observed in the class IV subgroup of BEST. Circulation. 2001;104:755.
22. Azevedo ER, Kubo T, Mak S, et al. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 2001;104:2194-9.
23. Bloem LJ, Manatunga AK, Pratt JH. Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity. Hypertension 1996;27:62-6.
24. Rotimi C, Puras A, Cooper R, et al. Polymorphisms of renin-angiotensin genes among Nigerians, Jamaicans, and African Americans. Hypertension 1996;27:558-63.
25. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A > G and c1165G > C. Hum Mutat 1999;14:271.
26. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
27. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group, Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
28. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
29. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
30. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-80.
31. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
32. MOCHA Investigators, Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
33. Packer M, Colucci WS, Sackner-Bernstein WS, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
34. US Carvedilol Heart Failure Study Group, Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
35. Cohn J.N., Bristow M.B. et al. Effects of carvedilol in severe heart failure. J Am Coll Cardiol. 1996;27:196.
36. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000;101:378-84.
37. Fowler M B, Carson P. Effect of carvedilol on frequency and severity of hospitalization in severe chronic heart failure: results of COPERNICUS study. Circulation. 2001;104:75.